Intravenous Infusions Past Earnings Performance
Past criteria checks 3/6
Intravenous Infusions's earnings have been declining at an average annual rate of -18.7%, while the Pharmaceuticals industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 4.8% per year. Intravenous Infusions's return on equity is 24.6%, and it has net margins of 16.1%.
Key information
-18.7%
Earnings growth rate
-22.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 4.8% |
| Return on equity | 24.6% |
| Net Margin | 16.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Intravenous Infusions makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 31 | 5 | 11 | 0 |
| 30 Jun 23 | 24 | 0 | 12 | 0 |
| 31 Mar 23 | 22 | -2 | 11 | 0 |
| 31 Dec 22 | 20 | -4 | 11 | 0 |
| 31 Dec 21 | 23 | 1 | 9 | 0 |
| 31 Dec 20 | 21 | 1 | 8 | 0 |
| 31 Dec 19 | 23 | 2 | 9 | 0 |
| 31 Dec 18 | 20 | 3 | 7 | 0 |
| 30 Sep 18 | 20 | 3 | 7 | 0 |
| 30 Jun 18 | 20 | 4 | 7 | 0 |
| 31 Mar 18 | 18 | 3 | 6 | 0 |
| 31 Dec 17 | 16 | 3 | 5 | 0 |
| 30 Sep 17 | 15 | 2 | 5 | 0 |
| 30 Jun 17 | 12 | 1 | 4 | 0 |
| 31 Mar 17 | 11 | 1 | 3 | 0 |
| 31 Dec 16 | 11 | 1 | 3 | 0 |
| 30 Sep 16 | 9 | 0 | 3 | 0 |
| 30 Jun 16 | 9 | 1 | 2 | 0 |
| 31 Mar 16 | 8 | 0 | 2 | 0 |
| 31 Dec 15 | 8 | -1 | 2 | 0 |
| 30 Sep 15 | 7 | 0 | 3 | 0 |
| 31 Dec 14 | 6 | -1 | 2 | 0 |
| 31 Dec 13 | 5 | 0 | 2 | 0 |
Quality Earnings: IIL has high quality earnings.
Growing Profit Margin: IIL became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IIL's earnings have declined by 18.7% per year over the past 5 years.
Accelerating Growth: IIL has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: IIL has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.4%).
Return on Equity
High ROE: IIL's Return on Equity (24.6%) is considered high.